Northridge, CA, USA, and Cambridge, United Kingdom, 11 February 2016 — Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specialising in the treatment of wounds and skin defects, today announced that it has appointed a distributor to sell its devices into the German, Austrian and Swiss markets.
MSM Medical sells advanced wound care products into the key German-speaking territories through its eight sales staff located in offices in Gomadingen, Vienna and Zurich. Avita Medical said it believed its regenerative medicine devices, which enable a clinician to rapidly create Regenerative Epithelial Suspension (RES™) by using a small sample of the patient’s skin, fitted well within MSM Medical’s product portfolio. The agreement, which came into commercial effect Feb. 10 will cover exclusive distribution across Avita’s full product range in Germany, Austria and Switzerland.
Avita Medical is rolling out its CE-marked product range across Europe by appointing distributors with longstanding relationships in the sector. The strategy is aimed at giving Avita a deeper reach and faster penetration into the burns, wound care and aesthetic surgery markets.
“When choosing a distributor, we must have comfort that they are able to effectively demonstrate to medical professionals how ReCell® can be deployed to benefit patients,” said Adam Kelliher, UK-based CEO of Avita Medical. “We quickly saw that MSM Medical have the appropriate expertise, and well-proven capabilities in supporting the sales of medical device products in the German-language wound care market.”
As with other distributor markets, Avita will support MSM Medical with publicity and clinical platforms, and a focused training programme for clinicians deploying the single-use device. The company recently announced appointments of distributors in the UK, France, Japan and South Korea, and said it has commenced commercial discussions with parties in other key territories.
ABOUT RECELL® AND RES™
ReCell® is Avita Medical’s unique proprietary technology that enables a clinician to rapidly create, at point of care in approximately 30 minutes, Regenerative Epithelial Suspension (RES™) using a small sample of the patient’s skin. RES™ is an autologous suspension comprising the cells and wound healing factors necessary to regenerate natural, healthy skin. RES™ has a broad range of applications and can be used to restart healing in unresponsive wounds, to repair burns using less donor skin yet with improved functional and aesthetic outcomes, and to restore pigmentation and improve cosmesis of damaged skin.
ABOUT AVITA MEDICAL LIMITED
Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita’s patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient’s own skin. The Company’s lead product, ReCell®, is used in the treatment of a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is patented, CE-marked for Europe, TGA-registered in Australia, and CFDA-cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use. A pivotal U.S. trial is underway, with patient enrollment completion anticipated by the end of 2015. To learn more, visit www.avitamedical.com.
